Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.88 |
| ▸ | NPC1 | O15118 | 3/20 | 0.88 |
| ▸ | RAB9A | P51151 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17257165 | 1.00 | GAA (0.88) | GAANPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL17257260 | 0.84 | NPC1 (0.72) | GAANPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL17257262 | 0.84 | NPC1 (0.72) | GAANPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL10798007 | 0.83 | NPC1 (0.70) | GAANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3080186 | 0.83 | NPC1 (0.70) | GAANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL3080187 | 0.83 | NPC1 (0.70) | GAANPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17256876 | 0.82 | NPC1 (0.62) | GAANPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL17256878 | 0.82 | NPC1 (0.62) | GAANPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL17256880 | 0.82 | NPC1 (0.62) | GAANPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL28114466 | 0.81 | KMT2A (0.60) | GAANPC1RAB9ASMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | claimed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| EP-3143055-B1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORP (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-0689549-B1 | NEW UREA DERIVATES, THEIR PREPARATION AND THEIR USE | HOECHST AG (DE) | 1998-06-17 | — | — | EP | disclosed |
| US-5703050-A | INHIBIT PLATELET AGGREGATION, METASTASIS OF CARCINOMA CELLS, OSTEOCLAST BINDING TO BONE SURFACE | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
| EP-0689549-A1 | NEW UREA DERIVATES, THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994022907-A1 | NEW UREA DERIVATES, THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | PAM, PPOX, MB | GAA 2104/4885NPC1 4775/4885RAB9A 4587/4885 |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | PAM, PPOX, MB | GAA 2104/4885NPC1 4775/4885RAB9A 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.